Pain experienced by patients with terminal head and neck carcinoma
โ Scribed by Yoav P. Talmi; Alexander Waller; Michaela Bercovici; Zeev Horowitz; M. Raphael Pfeffer; Abraham Adunski; Jona Kronenberg
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 83 KB
- Volume
- 80
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
Data pertaining to tumor origin, spread, treatment, and results were defined. Pain was assessed with the McGill Pain Questionnaire, using a 10-1 Department of Otolaryngology-Head and Neck point visual analogue scale (VAS) and a body map. Pain was diagnosed according Surgery, the Chaim Sheba Medical Center, Tel to cause and type. Treatment was selected according to the guidelines provided Hashomer, Israel.
in the WHO analgesic ladder.
๐ SIMILAR VOLUMES
Gm, A2m, and Km allotypic markers were examined in 40 Caucasian patients with squamous cell carcinomas of the head and neck. Serum IgA levels, the A2m(l) allotypic marker, and antibodies against IgAl, A2m(l), and A2m(2) were measured quantitatively. The frequency of Km(1) was found to be significant
Background. Comorbid conditions have a significant impact on the actuarial survival of patients with head and neck cancer. However, no studies have evaluated the impact of comorbidity on tumor-and treatment-specific outcomes. This study was performed to evaluate the impact of comorbidity, graded by